Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials
Cardiovascular Therapeutics · 08.08.2023 · 2023 · 1-11
DOI: 10.1155/2023/3121601 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cardiovascular Therapeutics, erschienen am 08.08.2023. Verfasst von Wenyi Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, Chi…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Lab for Cardiovascular Precision Medicine.
Abstract (Originalsprache)
Backgrounds. Many clinical trials have demonstrated the value of drug-coated balloons (DCB) for in-stent restenosis. However, their role in de novo lesions is not well documented. The aim of this study is to evaluate the safety and efficacy of the DCB-only strategy compared to other percutaneous coronary intervention strategies for de novo coronary lesions.
Methods
The PubMed, Embase, Web of Science, and Cochrane Library Central Register of Controlled Trials (CENTRAL) electronic databases were searched for randomized controlled trials published up to May 6, 2023. The primary outcomes were major adverse cardiac events and late lumen loss.
Results
A total of eighteen trials with 3336 participants were included. Compared with drug-eluting stents, the DCB-only strategy was associated with a similar risk of major adverse cardiac events (risk ratio RR = 0.90 ; 95% confidence interval (CI): 0.59 to 1.37, P = 0.631 ) and a significant decrease in late lumen loss (standardized mean difference SMD = − 0.29 , 95% CI: −0.53 to −0.04, P = 0.021 ). This effect was consistent in subgroup analysis regardless of indication, follow-up time, drug-eluting stent type, and dual antiplatelet therapy duration. However, DCBs were inferior to DESs for minimum lumen diameter and percentage diameter stenosis. The DCB-only strategy showed significantly better outcomes for most endpoints compared to plain-old balloon angioplasty or bare metal stents.
Conclusions
Interventions with a DCB-only strategy are comparable to those of drug-eluting stents and superior to plain-old balloon angioplasty or bare metal stents for the treatment of selected de novo coronary lesions. Additional evidence is still warranted to confirm the value of DCB before widespread clinical utilization can be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, China.
ORCID-Profile: Wenyi Zhang, Mingduo Zhang, Xiantao Song
Förderung
- Beijing Lab for Cardiovascular Precision Medicine
Zitieren
APA
Zhang, W., Zhang, M., Tian, J., Zhang, M., Zhou, Y., & Song, X. (2023). Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials. Cardiovascular Therapeutics, 2023, 1-11. https://doi.org/10.1155/2023/3121601
Vancouver
Zhang W, Zhang M, Tian J, Zhang M, Zhou Y, Song X. Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials. Cardiovascular Therapeutics. 2023;2023:1-11. doi:10.1155/2023/3121601
BibTeX
@article{Zhang2023,
author = {Zhang, Wenyi and Zhang, Mingduo and Tian, Jinfan and Zhang, Min and Zhou, Yuan and Song, Xiantao},
title = {Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials},
journal = {Cardiovascular Therapeutics},
year = {2023},
volume = {2023},
pages = {1--11},
doi = {10.1155/2023/3121601}
}
EUVIMED